Lupin will look to enjoy a seven-month advantage over its rival Indian firm Zydus Lifesciences in the race to debut generic competition to Neurocrine Biosciences’ Ingrezza (valbenazine) treatment for tardive dyskinesia in the US, after both companies in quick succession penned patent-litigation settlements.
Picking up the right to launch its proposed generic beginning 1 March 2038, Lupin faces a 14-year wait to launch...